Cargando…
Emerging treatments in the management of psoriasis: biological targeting with ustekinumab
Psoriasis is a chronic, genetically determined, immune-mediated, inflammatory skin disease affecting approximately 2% to 3% of Caucasian population. Given the well-established role of the immuno-mediated inflammation in the pathogenesis of psoriasis, in the past few years several key steps in the pa...
Autores principales: | Papoutsaki, Marina, Costanzo, Antonio, Chimenti, Sergio |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047931/ https://www.ncbi.nlm.nih.gov/pubmed/21436972 |
Ejemplares similares
-
Ustekinumab Treatment of Erythrodermic Psoriasis Occurring after Physical Stress: A Report of Two Cases
por: Saraceno, Rosita, et al.
Publicado: (2013) -
Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015) -
Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011) -
Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab
por: Garcia-Valladares, Ignacio, et al.
Publicado: (2011) -
Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab
por: Zhao, Yue, et al.
Publicado: (2014)